PHARMACY

Amgen's Kyprolis' new dosing option gets FDA nod

Amgen's Kyprolis now offers patients with relapsed or refractory multiple myeloma the option of a more convenient dosing regime.
Lupin receives FDA blessing for generic Pulmicort

Lupin has received the FDA's nod for generic Pulmicort, which had a market value of about $474.5 million.
Janssen gets FDA green light for new Invokana indication

Janssen's oral diabetes treatment is the first oral diabetes treatment to have an indication to reduce the risk of heart attack, stroke or cardiovascular death, the company said.
Cipla gets FDA OK for generic Valcyte

The FDA has approved Cipla's generic Valcyte, which had a market value of about $79 million.
FDA touts record-breaking number of October generic approvals

The Food and Drug Administration approved 110 generic drugs and tentatively approved 18 generic drugs for a total of 128 approval actions throughout the month of October.
Theravance Biopharma, Mylan get FDA approval for Yupelri

Yupelri is the first and only once-daily nebulized bronchodilator approved for the treatment of COPD, the companies said.
Lupin launches generic Mepron

Lupin is debuting a generic version of GlaxoSmithKline’s Mepron, which had a market value of about $119 million, according to IQVIA data.
Amneal, Lannett complete transition agreement for generic levothyroxine

Amneal’s agreement with Lannett accelerates the company's launch of the generic thyroid drug, levothyroxine.